ClinicalTrials.gg
Not yet recruitingNCT07538973Updated Apr 20, 2026

A Clinical Study to Evaluate the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects With Impaired Liver Function Versus Normal Liver Function

A Phase 1 interventional study of Anecatibin Fumarate Capsules in Lung Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Not yet recruiting at 3 sites in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-20.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 848 studies in Lung Neoplasms with a site in China — 374 open to participants now, 421 under way, 34 of them phase 3. Lung Neoplasms · China.

Planned enrollment
499th of 588
24 · median 90
Started
2026
with 89 others
Phase 1
75 of 848
44 open now
Primary completion
2027-03
later than 242 of 420 live
Registered
780th of 848
by date

Among the 848 studies in Lung Neoplasms with a site in China, this one is the 499th largest by planned enrollment of the 588 interventional ones that give a count, is one of 90 that started in 2026, is one of 75 in phase 1, reaches primary completion later than 242 of the 420 other live ones, and was the 780th registered.

Lung Neoplasms

5,434 studies on the registry are indexed under Lung Neoplasms; 1,348 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

374 of the 848 studies in Lung Neoplasms with a site in China are open now. Recruiting first, the newest first:

369 more — sign in →

All 374 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 996 Lung Neoplasms studies recruiting now, 685 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 848 studies in Lung Neoplasms with a site in China, or all of them as a file.
02

Study summary

Evaluation of the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects with Impaired Liver Function versus Normal Liver Function

03

Conditions studied

  • Lung Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All subjects must meet all of the following inclusion criteria:

  • Provide signed prior to trial participation and have a full understanding of the trial content, procedures, and potential adverse reactions;
  • Be male or female subjects aged 18 to 65 years (inclusive);
  • Weigh at least 50 kg for males and at least 45 kg for females. (BMI = weight (kg) / height² (m²)) within the range of 18 to 30 kg/m² (inclusive of boundary values);
  • Subjects and their partners agree to voluntarily adopt effective measures from screening until 6 months after the last dose;
  • Subjects are able to communicate well with the investigators and can complete the study according to the study protocol.

Subjects with normal liver function must also meet the following inclusion criteria:

  • Negative test results for surface antigen and antibody;
  • Normal liver function test results or abnormal results without clinical significance;
  • Matched with the hepatic impairment group in terms of male-to-female ratio (±1 subject per gender), mean age (±10 years), and mean body weight (±10 kg).

Subjects with hepatic impairment must meet the following inclusion criteria:

  • Have a history of or be diagnosed at screening with primary liver disease, including but not limited to: Hepatitis B, Hepatitis C, non-alcoholic fatty liver disease, alcoholic liver disease, etc.;
  • Hepatic impairment is caused by a previous primary liver disease (diagnosed at least 2 weeks prior to screening; excluding oncology patients) and is classified as Class A or B;
  • Liver function is stable within 2 weeks prior to taking the study drug, as determined by the investigator;
  • No medication for liver disease within 4 weeks prior to screening, or on a stable medication regimen for existing underlying conditions.

Exclusion criteria

Exclusion Criteria:

All subjects who meet any of the following exclusion criteria are not eligible for enrollment:

  • Suffering from primary diseases of major organs, including but not limited to gastrointestinal, respiratory, renal, neurological, hematological, endocrine, oncological, immune, psychiatric, or cardiovascular diseases, as determined by the Investigator to be unsuitable for participation in this trial (except for hepatic impairment patients regarding their primary liver disease and complications of hepatic impairment);
  • Physical examination, vital signs, or clinical laboratory tests (hematology, blood biochemistry, urinalysis, coagulation function) show abnormalities of clinical significance, as determined by the Investigator to be unsuitable for participation in this trial (except for hepatic impairment patients regarding their primary liver disease and complications of hepatic impairment);
  • Participated in any drug clinical trial and used any drug within 3 months prior to screening;
  • Tested positive for or syphilis screening;
  • Subjects with conditions that may affect the absorption, distribution, metabolism, or excretion of the study drug (e.g., inability to swallow) or who have undergone gastrointestinal resection that may affect drug absorption, distribution, metabolism, or excretion;
  • (ECG) abnormalities of clinical significance (e.g., tachycardia/bradycardia requiring medication, second- or third-degree atrioventricular block, or other abnormalities deemed and unsuitable for participation by the Investigator);
  • Used any inhibitors (e.g., macrolide antibiotics such as clarithromycin, triazole antifungals such as itraconazole, and HIV protease inhibitors such as lopinavir) or CYP3A4 inducers (e.g., rifampicin, carbamazepine, and phenytoin) within 4 weeks prior to screening;
  • Used any prescription drugs, over-the-counter medications, herbal medicines, or dietary supplements (e.g., vitamins, calcium supplements) within 2 weeks prior to screening, except for medications used by hepatic impairment patients to treat hepatic impairment and its complications;
  • Known allergy to any component of TQ-B3101 capsules, or having an allergic constitution (including a history of drug allergy, prone to rashes, eczema, urticaria, asthma, etc.);
  • Smoked an average of more than 5 cigarettes per day within 3 months prior to screening;
  • Has a history of drug abuse within 3 months prior to screening, or tested positive for urine drug screening;
  • Alcoholic liver disease patients have a history of alcoholism within 12 months prior to screening; other subjects have a history of alcoholism within 3 months prior to screening (average daily alcohol consumption > 2 units [1 unit = 360 mL beer or 45 mL 40% spirits or 150 mL wine]);
  • Donated blood or plasma, lost ≥ 200 mL of blood, or undergone plasmapheresis within 4 weeks prior to screening;
  • Consumed any food or beverage containing alcohol (or tested positive for alcohol breath test 1 day before dosing; alcoholic liver disease subjects consumed any alcohol-containing substances 2 weeks before dosing), grapefruit juice/pomelo juice, coffee, tea, cola, or chocolate within 1 week before dosing;
  • (CLcr) \< 60 mL/min (calculated by the Cockcroft-Gault formula);
  • Female subjects who are lactating or test positive for pregnancy during screening or the trial period;
  • Deemed by the Investigator to have any factors making them unsuitable for participation in this trial.

Subjects with hepatic impairment must also meet the following additional exclusion criteria:

  • History of liver transplantation;
  • Experienced hepatic encephalopathy within 30 days prior to screening;
  • Used any medication that may cause acute hepatotoxicity (e.g., halothane and methotrexate) within 3 months prior to screening;
  • Suffered from drug- or virus-induced acute hepatitis within 2 months prior to screening;
  • Experienced a rapid deterioration or /Aspartate Aminotransferase (ALT/AST) elevation > 3 times the within 2 weeks prior to dosing, as judged by the Investigator;
  • Experienced worsening of hepatic encephalopathy within 30 days prior to dosing;
  • Suffering from diseases affecting bile excretion, such as biliary cirrhosis, hepatic/biliary obstruction, or cholestatic liver disease;
  • Patients with liver failure or complications deemed unsuitable by the Investigator, such as hepatic encephalopathy, hepatocellular carcinoma, esophageal-gastric variceal bleeding within 3 months, severe portal hypertension, or history of portosystemic shunt surgery;
  • As judged by the Investigator, having concomitant medications that may potentially affect the evaluation of the pharmacokinetic characteristics of TQ-B3101 and its metabolites.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Anecatibin Fumarate Capsules (TQ-B3101 Capsules)

    The dose is 300 mg, administered once.

    Drug: Anecatibin Fumarate Capsules

Interventions

  • DrugAnecatibin Fumarate Capsules

    Anecatibin fumarate capsule is a prodrug that can be rapidly hydrolyzed into crizotinib in vivo to exert pharmacodynamic effects. Crizotinib is a tyrosine kinase receptor inhibitor, including Anaplastic lymphoma kinase (ALK), hepatocyte growth factor receptor Hepatocyte Growth Factor Receptor(HGFR, c-Met), ROS Proto-Oncogene 1, Receptor Tyrosine Kinase (ROS1, c-cos), and Recepteur d'Origine Nantais (RON).

06

What researchers measure

Primary outcomes

  1. To determine the Cmax

    To determine the Cmax of TQ-B3101 and its benzyloxypyridine metabolites.

    Time frame: The period extends from the date of the first dose to the completion of the EOT visit, totaling 5 days

  2. To determine the Area Under the Curve (AUC) 0-t

    To determine the AUC 0-t of TQ-B3101 and its benzyloxypyridine metabolites.

    Time frame: The period extends from the date of the first dose to the completion of the end of treatment (EOT) visit, totaling 5 days

  3. To determine the AUC 0-∞

    To determine the AUC 0-∞ of TQ-B3101 and its benzyloxypyridine metabolites.

    Time frame: The period extends from the date of the first dose to the completion of the EOT visit, totaling 5 days

Secondary outcomes

  1. Tmax of TQ-B3101 and its benzyloxy pyridine metabolite

    Obtain the Tmax of TQ-B3101 and its benzyloxy pyridine metabolite.

    Time frame: The period extends from the date of the first dose to the completion of the EOT visit, totaling 5 days

  2. t1/2 of TQ-B3101 and its benzyloxy pyridine metabolite

    Obtain the t1/2 of TQ-B3101 and its benzyloxy pyridine metabolite.

    Time frame: The period extends from the date of the first dose to the completion of the EOT visit, totaling 5 days

  3. Vz/F of TQ-B3101 and its benzyloxy pyridine metabolite

    Obtain the Vz/F of TQ-B3101 and its benzyloxy pyridine metabolite

    Time frame: The period extends from the date of the first dose to the completion of the EOT visit, totaling 5 days

  4. Apparent Clearance (CLz/F) of TQ-B3101 and its benzyloxy pyridine metabolite

    Obtain the CLz/F of TQ-B3101 and its benzyloxy pyridine metabolite.

    Time frame: The period extends from the date of the first dose to the completion of the EOT visit, totaling 5 days

  5. Numbers of subjects with adverse events

    Numbers of subjects with adverse events, including adverse events, clinical symptoms, physical examinations, vital signs (blood pressure, pulse, and body temperature), laboratory tests (hematology, blood biochemistry, urinalysis, coagulation function), and 12-lead electrocardiogram (ECG).

    Time frame: The period extends from the first dose date to the completion of the safety follow-up, not to exceed 90 days

07

Study locations

3 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Mar 2027, 11 months later.

Of 129 industry-sponsored phase 1 interventional studies under Lung Neoplasms, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 57. This study's planned 11 months is below that.

Counting every sponsor, half of 293 studies reached it within 52 months; a quarter within 28 and three quarters within 74.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2026
First posted
Apr 20, 2026
StartEst.
Apr 2026
Primary completionEst.
Mar 2027
CompletionEst.
Sep 2027
Last update
Apr 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07538973
Responsible party
Sponsor
First posted
Apr 20, 2026
Start date
Apr 2026 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Apr 20, 2026

Study contacts

Yu Cao, Doctor
Contact
Caoyu1767@126.com
18661809090

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion